A Japanese case of melanoma of unknown origin with a rare <i>BRAF</i><sup>V600R</sup> mutation was s...

Drug Discov Ther. 2022;16(5):256-257. (DOI: 10.5582/ddt.2022.01072)

A Japanese case of melanoma of unknown origin with a rare BRAF^V600R mutation was successfully treated with BRAF/MEK inhibitors

Kuriyama H, Kimura T, Mizuhashi S, Nishimura Y, Kanemaru H, Kajihara I, Makino K, Aoi J, Matsui H, Fukushima S

SUMMARY

Combination therapy with BRAF and MEK inhibitors (BRAF/MEKi) has shown significantly prolonged progression-free survival (PFS) and overall survival (OS) for BRAF mutated melanoma. Over 90% of the activating mutations are BRAF^V600E or BRAF^V600K changes. There are no reports of BRAF^V600R in Japanese patients with melanoma. The third most common BRAF mutation is BRAF^V600R. In this case, we detected the BRAF^V600R mutation with FoundationOne CDx in a Japanese patient with melanoma.. The patient was treated with BRAF/MEKi and maintained stable disease status for 1 year.

KEYWORDS: BRAF, V600R, melanoma, FoundationOne CDx

Full Text:

A Japanese case of melanoma of unknown origin with a rare BRAFV600R mutation was successfully treated with BRAF/MEK inhibitors

A Japanese case of melanoma of unknown origin with a rare BRAF^V600R mutation was successfully treated with BRAF/MEK inhibitors